Pfizer Inc. Stops Development of Danuglipron

In a significant development, Pfizer Inc. announced on Monday the discontinuation of its daily pill, danuglipron, aimed at chronic weight management. This decision comes after a trial participant suffered from drug-induced liver injury, marking a setback in the company's obesity treatment research.

Details of the Incident

The company revealed that during one of the dose-optimization studies, a participant experienced an elevation in liver enzymes. Importantly, the individual did not exhibit any liver-related symptoms or side effects, and enzyme levels normalized upon cessation of the pill.

Pfizer's Commitment to Obesity Research

Despite this hurdle, Pfizer remains committed to addressing the global challenge of obesity. Chris Boshoff, Pfizer's Chief Scientific Officer and President of R&D, emphasized the company's dedication to advancing treatments for cardiovascular and metabolic diseases. "We are focusing on our oral GIPR antagonist candidate and other early-stage obesity programs to meet the critical needs in patient care," Boshoff stated.